Sign up Australia
Proactive Investors - Run By Investors For Investors

Benitec endorsement of Pain Program from US and European clinical pain specialists

Benitec endorsement of Pain Program from US and European clinical pain specialists

Benitec's (ASX: BLT) company strategy is focused on developing new therapies for life-threatening diseases based on long-term silencing of genes.

In an update to the market, Benitec has highlighted that the company has received a strong endorsement of the Pain Program from U.S. and European clinical pain specialists.

Benitec is currently attempting to fast track the pre-clinical, clinical and commercial development of the company's lead program, which is a novel gene silencing therapeutic for intractable cancer-associated neuropathic pain.

In addition, Benitec has appointed U.S. based Ground Zero Pharmaceuticals as the CRO to advance the pain program into clinical testing under a USFDA-approved protocol.

Peter French, chief executive officer for Benitec, commented "These findings validate our pain program directly from the pain clinicians themselves.

"It reinforces our focus on the pain program, and provide the impetus for Benitec to mobilize additional resources to the program and to progress to the next stage of Benitec's commercial outreach for this program in the U.S. and Europe with Campbell Alliance."


Register here to be notified of future BLT Company articles
View full BLT profile

Benitec Biopharma Timeline

August 18 2015
November 11 2014

Related Articles

cancer cells
January 25 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
January 25 2017
At the moment, the healthcare firm M Pharma is a work in progress

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.